Jaka jest cena za Destiny Pharma plc (DEST)

Cena za Destiny Pharma plc (DEST) wynosi $0.04082105

Jaka jest kapitalizacja rynkowa dla Destiny Pharma plc (DEST)

Kapitalizacja rynkowa dla Destiny Pharma plc (DEST) wynosi $39.09K

Zyski Destiny Pharma plc (DEST)

Destiny Pharma plc is a biotechnology company based in Brighton, UK, founded in 1996, specializing in the identification, progression, and market introduction of pharmaceutical solutions for infectious diseases. The company's clinical pipeline includes NTCD-M3, currently in Phase III trials to prevent recurring Clostridioides difficile infections. Its XF-73 program features XF-73 Nasal, undergoing Phase II development for the prevention of post-surgical staphylococcal infections, and XF-73 Dermal, which is in Phase I for treating bacterial skin infections resistant to antibiotics. Additionally, Destiny Pharma's preclinical efforts involve SPOR-COV, a biotherapeutic product aimed at preventing COVID-19 and other viral respiratory diseases, and XF Drugs Biofilm, targeting antibiotic-resistant biofilm and bacterial aggregate infections. The company is also investigating further applications of its XF drugs for respiratory, oral mucosa, and ocular infections. Destiny Pharma maintains strategic alliances with various organizations, including China Medical System Holdings Limited, SporeGen Limited, the University of Southampton, Aston University, the University of Sheffield, Cardiff University, and Tianjin Medical University.

Rok	Zyski	Zmień
2026 (TTM)	$-8.21M	0.00%
2023	$-8.21M	-12.04%
2022	$-9.33M	10.03%
2021	$-8.48M	-4.31%
2020	$-8.86M	21.02%
2019	$-7.32M	-4.32%
2018	$-7.65M	76.32%
2017	$-4.34M	142.61%
2016	$-1.79M	1.42%
2015	$-1.76M	-45.18%
2014	$-3.22M	174.64%
2013	$-1.17M	0.00%

Rok

Zyski

Zmień

2026 (TTM)

$-8.21M

0.00%

2023

$-8.21M

-12.04%

2022

$-9.33M

10.03%

2021

$-8.48M

-4.31%

2020

$-8.86M

21.02%

2019

$-7.32M

-4.32%

2018

$-7.65M

76.32%

2017

$-4.34M

142.61%

2016

$-1.79M

1.42%

2015

$-1.76M

-45.18%

2014

$-3.22M

174.64%

2013

$-1.17M

0.00%

Firma	Zyski	Różnica w zyskach	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-64,380.54%	US
Argenx SE ARGX.US	$1.95B	-23,870.85%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$3.01B	-36,728.02%	BE

Firma

Zyski

Różnica w zyskach

Kraj